
Bionano Genomics (BNGO) Stock Forecast & Price Target
Bionano Genomics (BNGO) Analyst Ratings
Bulls say
Bionano Genomics demonstrated robust sales growth by selling 7,233 nanochannel array flowcells in 2Q25, representing a 17% increase from the previous year, and followed this with 8,390 sales in 3Q25, reflecting a 7% rise year-over-year. The company reported an 11% year-over-year increase in adjusted combined revenue for consumables, software, and remaining services in 2Q25, with consumables and software revenues specifically growing by 16%. Additionally, Bionano's outlook for new OGM installations in FY2025 has been raised to 20-25, indicating strong confidence in continued adoption of its technologies across various global regions, including Japan.
Bears say
Bionano Genomics faces several fundamental challenges that contribute to the negative outlook on its stock, including the risk of lower-than-anticipated market uptake and utilization of its Saphyr system. Additionally, the company's reliance on securing additional capital to fund operations introduces further uncertainty, as there is a possibility of dilution for shareholders. These risks, combined with a conservative expected revenue multiple, underscore the challenges the company faces in achieving its projected sales and sustaining financial health.
This aggregate rating is based on analysts' research of Bionano Genomics and is not a guaranteed prediction by Public.com or investment advice.
Bionano Genomics (BNGO) Analyst Forecast & Price Prediction
Start investing in Bionano Genomics (BNGO)
Order type
Buy in
Order amount
Est. shares
0 shares